Background: Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. We investigated oncogene-specific differences in these markers and clinical outcome.
Methods: Three cohorts of NSCLC patients with oncogene alterations (n=4189 total) were analyzed.
Breast Cancer Res Treat
October 2018
Purpose: To outline the demographics, clinical presentation, imaging features, and treatment modalities observed among a series of patients diagnosed with biopsy-proven granulomatous mastitis (GM).
Method: Following approval by institutional review board, retrospective chart review was performed on patients with biopsy-proven granulomatous mastitis at our institution in the period from January 2013 until October 2017.
Results: A total of 90 patients were identified: 87 women and 3 men.
© LitMetric 2025. All rights reserved.